eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
�we are glad that, at last, the commission is taking serious steps to fight air pollution before the court of justice,� clientearth lawyer ugo taddei said in a press release.